Henrik Klitgaard, PhD
Henrik Klitgaard, PhD, is currently Vice President, UCB Fellow, Neurosciences Therapeutic Area and is located in Braine-l’Alleud, Belgium. He received a PhD in Human Physiology in 1989 at the August Krogh Institute at the University of Copenhagen, Denmark. During his university career, Dr. Klitgaard worked at the Pasteur Institute in Paris, France, and at Harvard University, Boston, US.
Dr. Klitgaard has published around 100 peer-reviewed original papers, reviews and book chapters, and is a frequent speaker at neuroscience and epilepsy science meetings. His memberships and accolades include a position on the U.S. National Institute of Health’s epilepsy advisory committee and membership on the Neurobiology Committees of both the International League Against Epilepsy and American Epilepsy Society. In 2013 he was the recipient of the Lifetime Accelerator Award of the Epilepsy Therapy Project and Epilepsy Foundation for his contribution to the advancement of therapies for the treatment of epilepsy.
For more than 25 years, Dr. Klitgaard has conducted antiepileptic drug (AED) discovery in the pharmaceutical industry. He has contributed numerous publications on basic and applied aspects of epilepsy research and has frequently been an invited speaker at epilepsy congresses and meetings. During his career in the pharmaceutical industry, Dr. Klitgaard has been involved in the discovery and development of several AEDs at both Novo Nordisk A/S and at UCB, most notably Levetiracetam and Brivaracetam.